FDA Inspection 1209453 — Arizona Center for Reproductive Endocrinology & Infertility

Arizona Center for Reproductive Endocrinology & Infertility — FEI 3005391124

The FDA completed an inspection of Arizona Center for Reproductive Endocrinology & Infertility on June 28, 2023 in Tucson, AZ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 7 citations were issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
June 28, 2023
Fiscal Year
2023
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Tucson, AZ (United States)

Citations

IDCFRDescription
1221321 CFR 1271.47(a)Testing, screening, donor eligibility procedures
1223721 CFR 1271.55(a)(3)Summary--records used to make determination
1223921 CFR 1271.55(b)(2)Listing and interpretation of CD tests performed
1224221 CFR 1271.55(c)Name and personal info on accompanying records
1227721 CFR 1271.75(a)(1)Risk factors, clinical evidence
1228621 CFR 1271.80(b)Specimen collections not timely
1228721 CFR 1271.80(c)Kits not FDA approved, specifically labeled